Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03001895 | Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer | completed | Phase 2 | 120 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00022399 | Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 73 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 |
| clinicaltrials |
| NCT01257425 | Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg(PAMIS) | completed | Phase 2 | 109 | IpsenINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT02012920 | A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 200 | Innocrin PharmaceuticalINDUSTRY | 4 | Feb 1, 2019 | clinicaltrials |
| NCT02361086 | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 21 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02445976 | Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. | completed | Phase 2 | 197 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01664923 | Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer(STRIVE) | completed | Phase 2 | 396 | PfizerINDUSTRY | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02409212 | Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer(PANTERA) | completed | Phase 2 | 50 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01808222 | FACBC for Recurrent Prostate Cancer | completed | Phase 2 | 25 | David M. Schuster, MDOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01148069 | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers(TARGET) | completed | Phase 2 | 63 | Rennes University HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02047253 | Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment | completed | Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01832259 | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | completed | Phase 2 | 30 | University of UtahOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT00450463 | Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00499408 | Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 26 | Wake Forest University Health SciencesOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT00038181 | Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02107430 | Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer | completed | Phase 2 | 62 | SOTIO a.s.INDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00038246 | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00384839 | Vidaza to Restore Hormone Thx Prostate | completed | Phase 2 | 36 | US Oncology ResearchINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00599313 | Phase II Sunitinib Prog Met AIPC | completed | Phase 2 | 36 | US Oncology ResearchINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT01981122 | A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 52 | DendreonINDUSTRY | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01091103 | Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | completed | Phase 2 | 60 | PfizerINDUSTRY | 1 | Oct 23, 2018 | clinicaltrials |
| NCT01547299 | Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer | completed | Phase 2 | 52 | PfizerINDUSTRY | 2 | Oct 23, 2018 | clinicaltrials |
| NCT01620710 | Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes(PRIAMOS) | completed | Phase 2 | 80 | Heidelberg UniversityOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02153918 | Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00942578 | A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00436956 | AZD2171 to Treat Prostate Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00634647 | Satraplatin and Prednisone to Treat Prostate Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01302041 | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | completed | Phase 2 | 67 | Astellas Pharma IncINDUSTRY | 4 | Oct 2, 2018 | clinicaltrials |
| NCT01270880 | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01519414 | Tivantinib in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00467051 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | completed | Phase 2 | 20 | Children's Oncology GroupNETWORK | 4 | Aug 29, 2018 | clinicaltrials |
| NCT00400517 | GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer | completed | Phase 2 | 28 | The Cleveland ClinicOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01496157 | Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01815515 | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT00004149 | Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy | completed | Phase 2 | 37 | Albert Einstein College of MedicineOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00002943 | Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer | completed | Phase 2 | 11 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00345813 | Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer | completed | Phase 2 | 62 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00298155 | Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer(TAPS) | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01260688 | Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2018 | clinicaltrials |
| NCT00223665 | Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer(IAS) | completed | Phase 2 | 102 | University of WashingtonOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00283803 | Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00039624 | Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01656304 | Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 16 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00520481 | Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer | completed | Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2018 | clinicaltrials |
| NCT01045109 | Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.(D3/PCa) | completed | Phase 2 | 52 | Medical University of South CarolinaOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01054079 | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00272038 | Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer | completed | Phase 2 | 29 | Oncology Specialists, S.C.OTHER | 1 | Jun 27, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Feb 15, 2019source: clinicaltrials